Imaging biomarkers for diagnosis and treatment response in patients with lymphedema

Biomark Med. 2022 Mar;16(4):303-316. doi: 10.2217/bmm-2021-0487. Epub 2022 Feb 18.

Abstract

Lymphedema is defined as a dysfunction of the lymphatic system producing an accumulation of lymphatic fluid in the surrounding tissue, as well as edema and fibrosis. A total of 250 million people worldwide are affected by this condition. Greater than 99% of these cases are related to a secondary cause. As there is a lack of curative therapy, the goal involves early diagnosis, in order to prevent the progression of the disease. Additionally, early diagnosis can aid in decreasing the demand for more complex surgical procedures. Currently, there is an impressive breadth of diagnostic tests available for these patients. We aimed to review the available literature in relation to the utilization of imaging biomarkers for the early diagnosis and treatment response in lymphedema.

Keywords: bioimpedance spectroscopy; diagnostic imaging; lymphatic disfunction; lymphedema; lymphoscintigraphy; magnetic resonance imaging; tomography; ultrasonography; x-ray computed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Lymphedema* / diagnostic imaging
  • Lymphedema* / therapy
  • Lymphoscintigraphy* / adverse effects
  • Lymphoscintigraphy* / methods

Substances

  • Biomarkers